Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för camonsertib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2024-12-01

Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy.

Ng V, Sinha S, Novaj A, Ma J, McDermott N, Pei X, Longhini ALF, Grimsley H, Gardner R, Rosen E, Powell SN, Pareja F, Mandelker D, Khan A, Setton J, Roulston A, Morris S, Koehler M, Lee N, Reis-Filho J, Riaz N.

Clin Cancer Res · research-article; journal article · DOI 10.1158/1078-0432.ccr-24-0154

Bibliografisk träff 2024-12-01

Genomic Biomarkers Predict Response to Combined ATR Inhibition and Radiotherapy.

Schrank BR, Colbert LE.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-24-2306

Bibliografisk träff 2024-09-01

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).

Fontana E, Rosen E, Lee EK, Højgaard M, Mettu NB, Lheureux S, Carneiro BA, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA.

J Natl Cancer Inst · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1093/jnci/djae098

Bibliografisk träff 2024-02-20

Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib.

Papp R, Trimble L, Fretland AJ, Manohar R, Phipps R, Kvaerno L, Perryman AL, Reynolds G, Black WC.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.123.001611

Bibliografisk träff 2024-02-01

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.

Rosen E, Yap TA, Lee EK, Højgaard M, Mettu NB, Lheureux S, Carneiro BA, Plummer R, Fretland AJ, Ulanet D, Xu Y, McDougall R, Koehler M, Fontana E.

Clin Cancer Res · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-23-2080

Bibliografisk träff 2024-02-01

Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).

Black WC, Abdoli A, An X, Auger A, Beaulieu P, Bernatchez M, Caron C, Chefson A, Crane S, Diallo M, Dorich S, Fader LD, Ferraro GB, Fournier S, Gao Q, Ginzburg Y, Hamel M, Han Y, Jones P, Lanoix S, Lacbay CM, Leclaire ME, Levy M, Mamane Y, Mulani A, Papp R, Pellerin C, Picard A, Skeldon A, Skorey K, Stocco R, St-Onge M, Truchon JF, Truong VL, Zimmermann M, Zinda M, Roulston A.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.3c01917

Bibliografisk träff 2023-06-05

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.

Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E.

Nat Med · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1038/s41591-023-02399-0

Bibliografisk träff 2022-07-01

Guiding ATR and PARP inhibitor combinationswith chemogenomic screens.

Zimmermann M, Bernier C, Kaiser B, Fournier S, Li L, Desjardins J, Skeldon A, Rimkunas V, Veloso A, Young JTF, Roulston A, Zinda M.

Cell Rep · research support, non-u.s. gov't; journal article · DOI 10.1016/j.celrep.2022.111081

Bibliografisk träff 2021-12-15

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.

Roulston A, Zimmermann M, Papp R, Skeldon A, Pellerin C, Dumas-Bérube É, Dumais V, Dorich S, Fader LD, Fournier S, Li L, Leclaire ME, Yin SY, Chefson A, Alam H, Yang W, Fugère-Desjardins C, Vignini-Hammond S, Skorey K, Mulani A, Rimkunas V, Veloso A, Hamel M, Stocco R, Mamane Y, Li Z, Young JTF, Zinda M, Black WC.

Mol Cancer Ther · comment; research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1535-7163.mct-21-0615